FDA Grants Orphan Drug Designation to ATXA’s NTP42 for the Treatment of PAH
DUBLIN, IRELAND – March 8, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...
ATXA Therapeutics to Present at the 2018 Biotech and Money / Medtech and Money World Congress Showca
DUBLIN, IRELAND – February 2, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...
